628 692
the prostate in men with localised prostate cancer. Health Technol
Assess 2012;16:1–313
.
[49]
Briganti A, Larcher A, Abdollah F, et al. Updated nomogram pre- dicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012;61: 480–7.[50]
Briganti A, Chun FK, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenec- tomy in men with localized prostate cancer. Eur Urol 2006;50: 1006–13.
[51]
Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive pros- tate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–9.
[52]
Abdollah F, Karnes RJ, Suardi N, et al. Impact of adjuvant radiother- apy on survival of patients with node-positive prostate cancer. J Clin Oncol 2014;32:3939–47.
[53]
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42.[54]
Schreiber D, Wong AT, Rineer J, et al. Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study. J Clin Pathol 2015;68:453–7.[55]
Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatec- tomy. Eur Urol 2008;53:950–9.
[56]
Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011;107:765–70.
[57]
Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1–7, discussion 10-1.[58]
Joniau S, Briganti A, Gontero P, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-insti- tutional study. Eur Urol 2015;67:157–64.
[59]
Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta- analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.
[60]
Haglind E, Carlsson S, Stranne J, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatec- tomy: a prospective, controlled, nonrandomised trial. Eur Urol 2015;68:216–25.
[61]
Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate can- cer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
[62]
Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79:1310–7.
[63]
Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106–11.
[64]
Beckendorf V, Guerif S, Le Prise´ E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056–63.[65]
Heemsbergen WD, Al-Mamgani A, Slot T, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9.
[66]
Kalbasi A, Li J, Berman A, et al. Dose-escalated irradiation and overall survival in men with non-metastatic prostate cancer. JAMA Oncol 2015;1:897–906.
[67]
Dearnaley D, Syndikus I, Mossop H, et al. CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modu- lated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047–60.
[68]
Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III Non- inferiority Study Comparing Two Radiotherapy Fractionation Sche- dules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 2016;34:2325–32.[69]
Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061–9.
[70]
Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107–18.[71]
Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73.
[72]
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.[73]
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long- term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–90.
[74]
Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015;33:2143–50.[75]
Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015;16: 787– 94.
[76]
Lawton CA, DeSilvio M, Roach III M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/ radiation interactions. Int J Radiat Oncol Biol Phys 2007;69: 646–55.
[77]
James N, Spears MR, Clarke NW, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol 2016;2:348–57.
[78]
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long- term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
[79]
Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow- up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014;66: 243–50.
[80]
Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces riskE U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 1 8 – 6 2 9
628